Salix Pharmaceuticals Ltd. (SLXP) posted a third quarter loss of $7.3 million or $0.15 per share, compared to a loss of $5.4 million or $0.11 per share in the prior year period.
On average, nine analysts polled by Thomson Reuters expected the company to report a loss of $0.29 per share. Analysts' estimates typically exclude special items.
Total product revenue for the quarter was $65.7 million, compared to $42.9 million in last year period. Nine Wall Street analysts expected revenues of $60.42 million.
Looking forward, for the fourth quarter, the company expects product revenue to be approximately $68 million and a loss of approximately $0.14 per share.
Street analysts expect a loss of $0.03 per share on revenues of $72.28 million.
Further ahead, for the fiscal year 2009, the company expects total product revenue to be approximately $230 million, and a loss of approximately $0.90 per share.
Street analysts expect a loss of $0.92 per share on revenues of $230.18 million.
For comments and feedback: editorial@rttnews.com